Biotechnology firm Theolytics has been awarded €8 million research funding through the Horizon Europe programme, to support expansion of the OCTOPOD‑IV Phase IIa trial in platinum‑resistant ovarian cancer. The trial will evaluate THEO‑260 — a next‑generation oncolytic immunotherapy designed… Read More
Dave Cole, Head of Research, Accession Therapeutics, introduces a replicating viral platform for systemic tumour targeting. Cancer immunotherapy has transformed oncology. Immune checkpoint inhibitors and cell therapies have shown that the immune system can be mobilised to achieve durable tumour control. Yet for most patients, response rates… Read More
Two studies have uncovered how combining a reovirus with targeted cancer drugs can dramatically boost immune responses and tumour destruction – offering a promising route to more effective, personalised cancer therapies. Researchers at The Institute of Cancer Research, London, have shown that this combination involving virotherapy can… Read More
